Onconase
Navigation Links
Onconase in Medical News
Alfacell Announces Management Update
... rolling New Drug Application (NDA) submission for onconase in patients suffering from unresectable malignant ...eeting at the end of January 2009. About onconase (R) onconase is a first-in-class therapeutic product candidate ...Alfacell Reports Financial Results for First Quarter of Fiscal 2009
...leted a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...etails of the planned NDA submission. About onconase (R) onconase is a first-in-class therapeutic product candidate ...Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast
...nd other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of onconase in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com . Safe Harbor This press releas...Onconase in Medical Technology
Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies. In a chapter of the text th...Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirn...
Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase
BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...Researchers Identify Intracellular Pathway of Alfacell's Onconase
Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cell...Alfacell Provides Shareholder Update
...ofile, its ability to overcome MDR, I believe that onconase remains a viable candidate for second line therapy in MM. The fact that onconase was able to extend the lives of patients who had f...tudies on immune deficient mice to see what effect onconase would have on human tumors grafted onto these mice...Alfacell Provides ONCONASE(R) NDA Submission Update
... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme... planned submission of the final components of the onconase rolling NDA for patients that have failed prior ch...y. Therefore, the final components of the rolling onconase NDA will not be finalized until Alfacell receives ......py. The study demonstrated that the combination of onconase and rosiglitazone synergistically decreased cell v... The study concludes the novel drug combination of onconase and rosiglitazone is a promising combination. "T... in vivo studies and demonstrates the potential of onconase for effective use in cancer treatments via multipl...
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
...product in our oncology portfolio. We believe that onconase will prove to be a promising new treatment option ...with an ideal partner to maximize the potential of onconase in this region. We look forward to a successful co...llaboration with Megapharm." About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ...Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
...ry Phase IIIb clinical trial of its lead compound, onconase (ranpirnase), did not meet statistical significanc...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...ntering this clinical trial. Patients who received onconase plus doxorubicin experienced a MST of 10.5 months ...Onconase in Biological Technology
Alfacell Provides ONCONASE(R) NDA Submission Update
... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme...rom the confirmatory Phase IIIb clinical trial for onconase in patients suffering from UMM did not meet statis...ation effective as of January 1, 2009. About onconase (R) ......ct 4205 & 2008 112: Abstract 4010) report that onconase (ranpirnase) and R-Amphinase (R-Amph) show anti-tu...tment of Pathology at New York Medical College . onconase and R-Amph are amphibian endoribonucleases with un...ammed cell death) of malignant cells. Previously, onconase has been shown to affect multiple cellular pathway...
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...nd completion of the Phase IIIb clinical trial for onconase in UMM. In fiscal 2009, we plan to complete the ND...Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA
...n Cell Cycle (2008; Vol. 7, Issue 20) reports that onconase (ranpirnase) targets small interfering RNA (siRNA)...he expression was restored in the cells exposed to onconase for 48 or 72 hours. The data thus provide evidence...his data provide further evidence of the impact of onconase on the RNAi mechanism," said Kuslima Shogen, Alfac...Alfacell Hires Advisors to Advance Strategic Alternatives
...oved a specific transaction. About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ... A natural protein isolated from the leopard frog, onconase has been shown in the laboratory and clinic to tar...facell has licensed the U.S. commercial rights for onconase to Strativa Pharmaceuticals, a division of Par Pha...Alfacell Receives NASDAQ Delisting Letter
...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...Alfacell Receives NASDAQ Non-Compliance Notification
...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
...ent expectations for the planned completion of the onconase rolling NDA. The company will be eligible to recei...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...Alfacell Announces Retirement of Chief Executive Officer
...us upon receiving marketing approval by the FDA of onconase for the treatment of malignant mesothelioma, a sig...lfacell in the event aggregate annual net sales of onconase exceed $100 million. "Tina's contributions to Alfacell and the science behind onconase have been immeasurable," said David Sidransky, M.D...Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
... in the confirmatory Phase IIIb clinical trial for onconase (ranpirnase) in patients suffering from unresectab...rmaceutical, Inc. for the commercialization of onconase in the U.S. by Strativa, the branded product d...th BL&H Co. Ltd., for the commercialization of onconase in Korea, Taiwan and Hong Kong. Under the agr...Other TagsGenderDebateDebateTelecomHistoricHistoricMillerMillerFundsFundsAppletonImagesImagesOther Contentstryptophantryptophantryptophantryptophantubaltubaltuberculintuberculintuberculosistuberculosistuberculosistuberculosistuberculosistuberculosistubercletubercleacheache
(Date:11/26/2009)... Dr. David Kim of the Live Life Aga...y in Dallas , is one of a growing number of physic...etworking sites to connect with individuals who ar...fight morbid obesity. Dr. Kim is utilizing Faceboo... about his practice with the community. , ...
(Date:11/26/2009)... Benton Communications announces a ...h system for retailers struggling to make an econo...ovember 26, 2009 -- Flu fears is the type of chall...mergency room, according to Dr. David Benton, busi...d business growth system – The Rfactor Inte...
(Date:11/25/2009)..., EDINA, Minn., Nov. 25 ... of their dentist. But a chiropractor can also gi... Temporal-Mandibular Joint, which is where your ja...mporal bone). ,, The most common symptoms asso... clicking or popping of the jaw. But many other s...
(Date:11/25/2009)..., EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstC...X ) today announced that the company will host two... ,, December 7, 2009 - 9:00 a.m. CT/10:00 ...ss data presentations surrounding carfilzomib in r...tured at the 51st American Society of Hematology (...
(Date:11/25/2009)..., TORONTO, Nov. 25 /PRNewswire/ - Sentinelle Medic...s and advanced visualization software launches a s...its Aegis(TM) medical imaging software platform at... (RSNA) annual meeting in Chicago, Nov. 30 - Dec. ...erage the unique high quality images generated by ...
Breaking Medicine News(10 mins):Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 4[1] Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients[1] Pharmacist Injects Cure for Ailing Businesses [1] TMJ and Chiropractic Care: An Overall Wellness Approach[0] Onyx Pharmaceuticals Announces December 2009 Investor Events[1] Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology
(Date:11/24/2009)...ATON ROUGE Antarctica has long held secrets of th...til recently, there has been very little informati...th miles of ice for millions of years. Now, a team...LSU have been funded to the tune of $10 million d... to get to the bottom of things literally. These ...
(Date:11/23/2009)...hington, D.C. The community-associated strain of ...ria resistant to most common antibioticsposes a fa...is making its way into hospitals, according to a s... Diseases . , The new threat is easily picked u...aces and has increased the overall burden of MRSA ...
(Date:11/23/2009)...mington, CT Current research suggests that a comm...e. The related report by Nichols et al, "Unique L...w Class of TLR2 Ligands Capable of Enhancing Autoi...e American Journal of Pathology . , Multiple sc...tacks the brain and spinal cord, affects nearly 1 ...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Sinovac Schedules 2008 Annual General Meeting 48447 1Sinovac Schedules 2008 Annual General Meeting 48447 2The University of Miami Miller School of Medicine the City of Miami Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Us 48442 1The University of Miami Miller School of Medicine the City of Miami Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Us 48442 2The University of Miami Miller School of Medicine the City of Miami Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Us 48442 3American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 1American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 2American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 3American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |